Leptin (116-130), amide, mouse: Precision Tools for Obesity and Metabolic Research

Understanding the Principle: From Adipocyte-Derived Hormone to Applied Models

Leptin (116-130), amide, mouse, is a bioactive peptide fragment derived from the central adipocyte-derived hormone leptin. Its sequence—Ser-Cys-Ser-Leu-Pro-Gln-Thr-Ser-Gly-Leu-Gln-Lys-Pro-Glu-Ser-NH₂—retains critical signaling capacity, enabling investigators to interrogate energy homeostasis regulation, food intake, and the pleiotropic effects of leptin across metabolic and immune systems. By mimicking the physiological actions of native leptin, this fragment provides a controlled yet potent tool for obesity and diabetes research, as well as for dissecting leptin resistance and deficiency states. The product is supplied as an easy-to-dissolve solid, with exceptional solubility in DMSO (≥156 mg/mL) and water (≥24.15 mg/mL), supporting a wide range of in vitro and in vivo protocols (learn more).

Stepwise Experimental Workflow and Protocol Enhancements

Translational and preclinical studies leverage Leptin (116-130), amide, mouse to create reproducible metabolic phenotypes and to probe the leptin signaling pathway with fine control. Below, we outline a generalized workflow supported by best practices from the literature and APExBIO's technical guidance.

Protocol Parameters

• Stock Solution Preparation: Dissolve the peptide to a final concentration of 1–10 mM in DMSO or 2–5 mM in sterile water. Filter-sterilize using a 0.22 μm syringe filter. Prepare fresh aliquots and store at -20°C, protected from moisture.
• In Vivo Administration: Typical dosing in mouse models ranges from 0.5–2 mg/kg body weight, administered via intraperitoneal injection daily for 2–4 weeks to model chronic metabolic effects (see applied workflows).
• In Vitro Cellular Assays: Treat cultured adipocytes or immune cells with 0.1–10 μM peptide for 12–48 hours, adjusting concentration based on cell type sensitivity and readout endpoints (e.g., STAT3 phosphorylation, glucose uptake).

Advanced Applications and Comparative Advantages

The ability of Leptin (116-130), amide, mouse to modulate food intake, body weight, and metabolic signaling is directly translatable to several experimental contexts:

• Obesity and Diabetes Research: By recapitulating key aspects of the leptin signaling pathway, this peptide fragment enables precise modeling of leptin sensitivity, resistance, and deficiency. Direct comparison with full-length leptin reveals that the 116-130 fragment maintains bioactivity while reducing off-target effects and immunogenicity, facilitating chronic administration and mechanistic dissection (protocol advantages).
• Immunometabolic Crosstalk: Studies have demonstrated the utility of Leptin (116-130), amide, mouse in characterizing the interplay between metabolic and immune responses, including T cell activation and cytokine production, thereby extending its value to autoimmune and inflammatory disease models (mechanistic frameworks).
• Energy Homeostasis Regulation: Well-suited to probing hypothalamic control of appetite and energy expenditure, the peptide supports both acute and chronic intervention studies—essential for mapping regulatory circuits and testing anti-obesity therapeutics.

Compared to recombinant full-length leptin, the 116-130 fragment offers enhanced stability and reduced aggregation, making it optimal for repeated dosing and long-term studies. Its high solubility and defined sequence also minimize batch-to-batch variability—a critical factor for robust, reproducible science.

Key Innovation from the Reference Study

The recent study on berberine’s inhibition of NLRP3 inflammasome activation via the SIRT6-AMPK pathway (International Immunopharmacology) provides a mechanistic bridge for immunometabolic research. The demonstration that SIRT6-AMPK signaling can modulate inflammatory and fibrotic processes in cardiac tissue suggests parallel avenues for leptin fragment intervention, especially in models where metabolic dysregulation intersects with chronic inflammation. Practically, this insight supports the inclusion of SIRT6 and AMPK functional readouts (e.g., phosphorylation assays, qPCR for pathway genes) when using Leptin (116-130), amide, mouse in metabolic or cardiovascular protocols. Moreover, this cross-pathway analysis can inform the design of co-treatment studies, where leptin fragments and small-molecule modulators are combined to dissect synergistic or antagonistic effects on metabolic and inflammatory endpoints.

Workflow Integration: Comparative and Complementary Literature

Several in-depth guides expand on the practical deployment of Leptin (116-130), amide, mouse. For example, "Applied Workflows with Leptin (116-130), amide, mouse in Obesity Models" offers stepwise protocols and troubleshooting strategies for metabolic phenotyping, complementing the current article’s focus on immunometabolic endpoints. Meanwhile, "Applied Protocols & Assay Advantages" contrasts dosing regimens and highlights assay-specific benefits, such as improved signal-to-noise ratio in hormone-sensitive assays. Together, these resources provide a comprehensive foundation for optimizing experimental design and maximizing the translational impact of leptin fragment research.

Troubleshooting and Optimization Tips

• Peptide Solubility: Always dissolve Leptin (116-130), amide, mouse in DMSO or sterile water; avoid ethanol due to insolubility. For high concentrations, gentle vortexing or brief sonication may help achieve complete dissolution.
• Aliquoting and Storage: Prepare single-use aliquots and store desiccated at -20°C. Avoid repeated freeze-thaw cycles, which can degrade the peptide and alter bioactivity. Use freshly prepared solutions promptly; do not store diluted stocks long-term.
• In Vivo Dosing Consistency: Standardize administration time and route (e.g., always inject intraperitoneally at the same circadian phase) to reduce biological variability.
• Assay Controls: Include both vehicle and full-length leptin controls where possible to benchmark the specific actions of the 116-130 fragment and to detect potential off-target effects.
• Readout Optimization: When studying immunometabolic endpoints, pilot test multiple time points (e.g., 6, 24, and 48 hours post-treatment) to capture dynamic pathway activation, especially for SIRT6-AMPK and NLRP3 inflammasome markers.

Why This Cross-Domain Matters, Maturity, and Limitations

The intersection of metabolic and inflammatory pathways is a rapidly evolving area of research. Leveraging insights from inflammasome modulation in cardiovascular disease (as demonstrated by the SIRT6-AMPK pathway study) enables researchers to apply Leptin (116-130), amide, mouse not only in classical models of obesity and diabetes but also in settings where metabolic stress drives immune dysfunction. However, while preclinical evidence is strong, translational maturity remains limited by species differences and the need for further validation in human tissues. Researchers should interpret cross-domain results with caution and rigorously control for model-specific variables.

Future Outlook: Implications and Next Steps

Emerging studies underscore the potential of Leptin (116-130), amide, mouse in bridging metabolic and immunometabolic disease research. The ability to integrate pathway-level readouts, such as SIRT6-AMPK and NLRP3 inflammasome activation, positions this peptide as a key tool for unraveling complex disease mechanisms and for preclinical therapeutic screening. As more robust cross-domain assays are developed—leveraging insights from both metabolic and cardiovascular research—APExBIO's commitment to quality and reproducibility will support the next generation of translational breakthroughs. For details on ordering and technical support, visit the Leptin (116-130), amide, mouse product page.